|Bid||1.2000 x 800|
|Ask||0.0000 x 800|
|Day's range||1.4800 - 1.6000|
|52-week range||0.8550 - 2.9400|
|Beta (5Y monthly)||0.07|
|PE ratio (TTM)||N/A|
|Earnings date||29 Apr 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
NEW YORK & LONDON & PARIS, May 17, 2022--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that Mr. Darren Lui, President and Executive Director of Aptorum Group will present virtually at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
NEW YORK & LONDON & PARIS, May 02, 2022--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, is pleased to announce the finalized data from the Phase 1 clinical trial of SACT-1, a repurposed small molecule drug targeting Neuroblastoma and potentially other cancer types.